Rodeo Therapeutics, a Seattle, WA-primarily based totally corporation growing small-molecule treatment plans designed to sell regeneration and restore of more than one tissue types, raised $5.9m in Series A financing.
Backers covered AbbVie Ventures, Alexandria Venture Investments, ARCH Venture Partners, Eli Lilly and Company, Johnson & Johnson Innovation – JJDC, Inc., Watson Fund, L.P., WRF Capital and WuXi AppTec.
Founded via way of means of Sanford Markowitz, M.D., Ph.D., the Markowitz-Ingalls Professor of Cancer Genetics and Distinguished University Professor at Case Western Reserve University School of Medicine, Stanton Gerson, M.D., and Joseph Ready, Ph.D., Rodeo Therapeutics is targeted on growing small-molecule treatment plans that growth tissue stages of prostaglandin PGE2.
Preclinical research posted in Science have proven that growing PGE2 thru inhibition of a prostaglandin-degrading enzyme (15-PGDH) hurries up hematopoietic stem mobileular reconstitution following bone marrow transplant, protects in opposition to colitis and promotes liver regeneration in numerous animal models.
The corporation will to begin with cognizance on growing 15-PGDH inhibitors for the remedy of inflammatory bowel sickness and selling blood mobileular reconstitution following bone marrow transplant.
